Rhythm Pharmaceuticals, Inc. (RYTM) Dividend History

Company News

• Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

  Rhythm Pharmaceuticals reported strong Q1 2025 results, with $37.7 million in net product revenue from IMCIVREE and positive data from its pivotal Phase 3 trial of setmelanotide in acquired hypothalamic obesity. The company also provided updates on its pipeline and anticipated upcoming milestones.

  GlobeNewswire Inc.
• Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

  Rhythm Pharmaceuticals announced positive topline results from its pivotal Phase 3 TRANSCEND trial evaluating setmelanotide for the treatment of acquired hypothalamic obesity. The trial met its primary endpoint with a statistically significant and clinically meaningful reduction in body mass index (BMI) with setmelanotide compared to placebo in both adult and pediatric patients.

  GlobeNewswire Inc.
• Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

  Rhythm Pharmaceuticals and the Raymond A. Wood Foundation have announced a new research collaboration to study the impact of fatigue on persons with craniopharyngioma, a rare neuroendocrine disease. The goal is to better understand the experiences of craniopharyngioma survivors and factors that may affect fatigue, such as weight gain and daytime sleepiness.

  GlobeNewswire Inc.
• Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight

  The obesity market is projected to grow from 2024 to 2034 due to the rising prevalence of obesity and the extensive pipeline of emerging drugs with improved safety profiles. The article discusses different types of obesity, including hypothalamic, pediatric, POMC deficiency, and syndromic/monogenic obesity, and the current treatment landscape and pipeline for each.

  GlobeNewswire Inc.

  Featured Companies: AARD ALT LLY PFE SLNO
• Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

  Rhythm Pharmaceuticals and Axovia Therapeutics have announced a joint research collaboration to advance the understanding of Bardet-Biedl syndrome, a rare genetic disorder. The collaboration aims to improve the lives of patients and their families living with this disease.

  GlobeNewswire Inc.